Drug-induced Liver Injury Is Modulated By Gut Microbiota
Gut bacteria may selectively modify the breaking down of a drug, pharmaceutical scientists from the National University of Singapore report in a new study. This causes certain patients to suffer from drug-induced liver injury (DILI), where there are unexpected side effects from consuming a drug, causing liver damage.
The discovery and understanding of this process could potentially lead to the development of novel strategies to improve drug treatment outcomes and reduce drug-associated side effects.
Pharmaceutical drugs are broken down by enzymes in the liver into their metabolites, which are subsequently excreted in the feces and urine. Drugs can also undergo chemical reactions mediated by bacteria within the gut, an important process that is commonly neglected.
Microbe Influences On Drugs
The study was conducted using tacrine, an anti-Alzheimer’s disease drug which may cause unintended liver damage.
Led by Prof Eric Chan from the Department of Pharmacy, NUS, the research was carried out in collaboration with scientists from GlaxoSmithKline, Department of Microbiology, Department of Surgery and Genome Institute of Singapore.
“To date, the influence of microbes on the fate of drugs is only established for a small fraction of marketed medicines. The contribution of gut microbiota towards variation in the response of individuals to a given drug remains poorly understood. This difference in the response to drug therapy is clinically important and poses a major challenge to both drug development and patient management,”
said Prof Chan.
Enhanced Enterohepatic Recycling
The research team found that rats suffering from drug-induced liver injury experienced a process termed enhanced enterohepatic recycling, where the excreted metabolite of the drug in bile is reconverted back to the parent drug by gut bacteria and reabsorbed into the body from within the gut.
The DILI rats were found to have a greater amount of a specific bacteria that can enable this drug reconversion process. When this bacteria is made inactive, the research team found that there is less injury to the liver.
“Our study establishes the gut microbial influences which cause unintended liver damage when using the drug tacrine, providing crucial insights for the development of personalised medicine initiatives.”
Dr Yip Lian Yee, who is the first author of the study, said.
“Our study confirms for the first time that the liver-gut microbial community has an influence on unintended liver damage caused by tacrine in rodent models. While this study is focused on tacrine, our findings hold pertinent implications for other therapeutic drugs with side effects, particularly those that undergo extensive enterohepatic recycling, demonstrate large variations between individuals and exhibit narrow therapeutic indices,”